Physician profile
Katrina M Pack
NPI 1144517947
$2,521.36
in general payments reported to CMS, 2019-2025
27 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $105 · 2021: $569 · 2022: $301 · 2023: $346 · 2024: $180 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.41 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $506.24 | 2019-2023 | Tysabri, Vumerity |
| Amgen INC. | $376.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $270.28 | 2019-2023 | |
| Emd Serono, INC. | $203.75 | 2019-2023 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $175.21 | 2021 | |
| Abbvie INC. | $138.48 | 2021-2025 | |
| Pfizer INC. | $135.35 | 2023-2025 | |
| Ucb, INC. | $90.93 | 2019-2025 | Rystiggo |
| Abbott Laboratories | $86.66 | 2022-2024 | Infinity |
| Neurocrine Biosciences, INC. | $76.45 | 2022-2024 | Ingrezza, Ongentys |
| Mallinckrodt Enterprises LLC | $55.37 | 2019 | |
| Argenx US, INC. | $54.74 | 2022-2024 | Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $46.24 | 2020-2021 | |
| Allergan, INC. | $43.48 | 2019-2021 | |
| Boston Scientific Corporation | $37.93 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $28.66 | 2022 | |
| Amneal Pharmaceuticals LLC | $27.94 | 2025 | Ongentys |
| Acadia Pharmaceuticals INC | $20.68 | 2025 | Nuplazid |
| Medtronic, INC. | $20.23 | 2021 | |
| Akcea Therapeutics, INC. | $19.55 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.30 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.83 | 2019 | |
| Celgene Corporation | $15.45 | 2023 | Zeposia |
| Grifols USA, LLC | $14.08 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.70 | 2019 | |
| Lundbeck LLC | $13.68 | 2021 | |
| Upsher-Smith Laboratories LLC | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Pack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.